Drug Profile
JCAR 018
Alternative Names: Anti-CD22 chimeric antigen receptor T cell therapy - National Cancer Institute/Opus Bio; Anti-CD22 human single chain variable fragment CAR T cell therapy - National Cancer Institute/Opus Bio; Anti-CD22-CAR T cell therapy - National Cancer Institute/Opus Bio; anti-CD22-CAR transduced T cells - National Cancer Institute/Opus Bio; Anti-CD22-human scFv CAR T cell product - National Cancer Institute/Opus Bio; Anti-CD22-human scFv CAR T cell therapy - National Cancer Institute/Opus BioLatest Information Update: 17 Nov 2023
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); Opus Bio
- Developer National Cancer Institute (USA)
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 13 Nov 2023 National Cancer Institute suspends patient enrolment in a phase I trial in Acute lymphoblastic leukaemia & Non-Hodgkin's lymphoma (Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (IV) (NCT02315612)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV, Infusion)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV, Infusion)